# ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Source: https://onco.cc/trials/nct06321081/  
OnCo record `nct06321081` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Beijing Hospital, now recruiting.

## Summary

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC is a phase 2, interventional study registered as NCT06321081 by Beijing Hospital, with a registry enrolment figure of 60 participants, started 2024-03-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: irinotecan, cetuximab, envafolimab. Conditions listed: RAS Mutation; Metastatic Colorectal Cancer; MSS. Primary outcome: progression free survival. Colorectal eligibility wording from the registry: "Histologically proven diagnosis of colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06321081
- Phase: 2
- Setting: ICE Study: a Clinical Study of the Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
- Sponsor: Beijing Hospital
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06321081: https://clinicaltrials.gov/study/NCT06321081

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06321081.json